Contents
Issue 148 • November 2024
In association with
In Depth
Cell and gene therapy approvals drive paradigm change in manufacturing
After the Lykos debacle, what’s next for psychedelic therapies?
Compounding pharmacies caught in counterfeit controversy
How the Covid-19 pandemic will help researchers with the mpox emergency
Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
Clinical research in the UK must build on industry collaboration, says NIHR director
Keytruda and Opdivo: a decade review
